The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia

Brain Research Bulletin

Volumn 77, Issue 1, 2008, Pages 33-41

  Miller, Christine L ^a   Dulay, Jeannette R ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

G protein coupled receptor GPR109 A; Nicotinic acid; Psychosis; Quantitative Western blots; Real time PCR human postmortem tissue

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NIACIN RECEPTOR HM74A; RECEPTOR PROTEIN;

ADULT; ANALYTICAL ERROR; ARTICLE; BINDING AFFINITY; BIODEGRADATION; BIPOLAR DISORDER; CINGULATE GYRUS; CONTROL GROUP; CONTROLLED STUDY; FEMALE; GEL; GENE CONTROL; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ADULT; BIPOLAR DISORDER; BLOTTING, WESTERN; BRAIN; FEMALE; GENE EXPRESSION; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; NIACIN; POSTMORTEM CHANGES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

EID: 51749124907     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2008.03.015     Document Type: Article

References (56)

1. Atlas A., Gisslen M., Nordin C., Lindstrom L., and Schwieler L. Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid. Brain Behav. Immun. 21 (2007) 86-91
2. Atz M., Walsh D., Cartagena P., Li J., Evans S., Choudary P., Overman K., Stein R., Tomita H., Potkin S., Myers R., Watson S.J., Jones E.G., Akil H., Bunney Jr. W.E., and Vawter M.P. Members of National Institute of Mental Health Conte Center and Pritzker Neuropsychiatric Disorders Research Consortium, methodological considerations for gene expression profiling of human brain. J. Neurosci. Methods 163 (2007) 295-309
3. Avalos J.L., Bever K.M., and Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol. Cell 17 (2005) 855-868
4. Babcock J.W. The prevalence and psychology of pellagra. Am. J. Psychiatry 67 (1911) 517-540
5. Badaway A.B., and Evans M. The regulation of rat liver tryptophan pyrrolase activity by reduced nicotinamide-adenine dinucleotide (phosphate). Biochem. J. 156 (1976) 381-390
6. Belenky P., Bogan K.L., and Brenner C. NAD+ metabolism in health and disease. Trends Biochem. Sci. 32 (2007) 12-19
7. Benyo Z., Gille A., Kero J., Csiky M., Suchankova M.C., Nusing R.M., Moers A., Pfeffer K., and Offermanns S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest. 115 (2005) 3634-3640
8. Calder P.C. Polyunsaturated fatty acids and inflammation. Biochem. Soc. Trans. 33 (2005) 423-427
9. Chang J.Y.L. Bile acid regulation of hepatic physiology. III. Bile acids and nuclear receptors. Am. J. Physiol. Gastrointest. Liver Phys. 284 (2003) G349-G356
10. Cheng K., Wu T.J., Wu K.K., Sturino C., Metters K., Gottesdiener K., Wright S.D., Wang Z., O'Neill G., Lai E., and Waters M.G. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. 103 (2006) 6682-6687
11. Cho-Chung Y.S., and Pitot H.C. Feedback control of rat liver tryptophan pyrrolase. J. Biol. Chem. 242 (1967) 1192-1198
12. Fiedler P., Wolkin A., and Rotrosen J. Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics. Biol. Psychiatry 21 (1986) 1344-1347
13. Gallo C.M., Smith D.L., and Smith J.S. Nicotinamide clearance by Pnc1 directly regulates Sir2-mediated silencing and longevity. Mol. Cell. Biol. 24 (2004) 1301-1312
14. Heckers S., and Goff D.C. Neural circuitry and signalling in schizophrenia. In: Kaplan G.B., and Hammer R.P. (Eds). Brain Circuitry and Signalling in Psychiatry (2002), American Psychiatric Publishing, Inc., Arlington 67-97
15. Hoffer A., Osmond H., Callbeck M.J., and Kahan I. Treatment of schizophrenia with nicotinic acid and nicotinamide. J. Clin. Exp. Psychopathol. 18 (1957) 131-158
16. A. Hoffer, Niacin Therapy in Psychiatry, C.C. Thomas, Springfield, 1962, p. 10.
17. Horrobin D.F. Niacin flushing, prostaglandin E and evening primrose oil: a possible objective test for monitoring therapy in schizophrenia. Orthomol. Psychiatry 9 (1980) 33-34
18. Hudson C.J., Lin A., Cogan S., Cashman F., and Warsh J.J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?. Biol. Psychiatry 41 (1997) 507-513
19. Hughes J.R., Hatsukami D.K., Mitchell J.E., and Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry 143 (1986) 993-997
20. Kleijnen J., and Knipschild P. Niacin and vitamin B6 in mental functioning: a review of controlled trials in humans. Biol. Psychiatry 29 (1991) 931-941
21. Knowles H.J., te Poele R.H., Workman P., and Harris A.L. Niacin induces PPAR gamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem. Pharmacol. 71 (2006) 646-656
22. Kristiansen L.V., Beneyto M., Haroutunian V., and Meador-Woodruff J.H. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol. Psychiatry 11 (2006) 737-747
23. Lorenzen A., Stannek C., Lang H., Andrianov V., Kalvinsh I., and Schwabe U. Characterization of a G protein-coupled receptor for nicotinic acid. Mol. Pharmacol. 59 (2001) 349-357
24. Malcolm R. Nicotinic acid and depression: depression following cessation of nicotinic acid use. Psychosomatics 16 (1975) 68-69
25. McCoy J.M., Wicks J.R., and Audoly L.P. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 110 (2002) 651-658
26. Messamore E., Hoffman W.F., and Janowsky A. The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. Schizophr. Res. 62 (2003) 251-258
27. Mexal S., Berger R., Adams C.E., Ross R.G., Freedman R., and Leonard S. Brain pH has a significant impact on human postmortem hippocampal gene expression profiles. Brain Res. 1106 1 (2006) 1-11
28. Miller C.L., Diglisic S., Leister F., Webster M., and Yolken R.H. Evaluating RNA status for RT-PCR in extracts of postmortem human brain tissue. Biotechniques 36 (2004) 628-633
29. Miller C.L., Llenos I.C., Dulay J.R., Barillo M.M., Yolken R.H., and Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis. 15 (2004) 618-629
30. Miller C.L., Llenos I.C., Dulay J.R., and Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 1073-1074 (2006) 25-37
31. Murphy P., Likhodii S., Nylen K., and Burnham W.M. The antidepressant properties of the ketogenic diet. Biol. Psychiatry 56 (2004) 981-983
32. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol. Sci. 27 (2006) 384-390
33. Oken R.J., and Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr. Bull. 25 (1999) 625-638
34. Richelsen B., and Beck-Nielsen H. Decrease of prostaglandin E2 receptor binding is accompanied by reduced antilipolytic effects of prostaglandin E2 in isolated rat adipocytes. J. Lipid Res. 26 (1985) 127-134
35. Ross B.M., Hughes B., Turenne S., Seeman M., and Warsh J.J. Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry. Eur. Neuropsychopharm. 14 (2004) 191-197
36. Rybakowski J., and Weterle R. Niacin test in schizophrenia and affective illness. Biol. Psychiatry 29 (1991) 834-836
37. Sandmeier J.J., Celic I., Boeke J.D., and Smith J.S. Telomeric and rDNA silencing in Saccharomyces cerevisiae are dependent on a nuclear NAD(+) salvage pathway. Genetics 160 (2002) 877-889
38. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., and Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50 (2001) 521-530
39. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47 (2002) 27-38
40. Serretti A., De Ronchi D., Lorenzi C., and Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr. Med. Chem. 11 (2004) 343-358
41. Shah S.H., Vankar G.K., Peet M., and Ramchand C.N. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr. Res. 43 (2000) 163-164
42. Shibata Y. On the regulation of tryptophan metabolism "via" kynurenine. Acta Vitaminol. Enzymol. 32 (1978) 195-207
43. Smesny S., Rosburg T., Riemann S., Baur K., Rudolph N., Berger G., and Sauer H. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 72 (2005) 393-402
44. Soga T., Kamohara M., Takasaki J., Matsumoto S., Saito T., Ohishi T., Hiyama H., Matsuo A., Matsushime H., and Furuichi K. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. 303 (2003) 364-369
45. Taggart A.K., Kero J., Gan X., Cai T.Q., Cheng K., Ippolito M., Ren N., Kaplan R., Wu K., Wu T.J., Jin L., Liaw C., Chen R., Richman J., Connolly D., Offermanns S., Wright S.D., and Waters M.G. (d)-Beta-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem. 280 (2005) 26649-26652
46. Talbot K., Eidem W.L., Tinsley C.L., Benson M.A., Thompson E.W., Smith R.J., Hahn C.G., Siegel S.J., Trojanowski J.Q., Gur R.E., Blake D.J., and Arnold S.E. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J. Clin. Invest. 113 (2004) 1353-1363
47. Tang Y., Zhou L., Gunnet J.W., Wines P.G., Cryan E.V., and Demarest K.T. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem. Biophys. Res. Commun. 345 (2006) 29-37
48. Torhan A.S., Cheewatrakoolpong B., and Greenfeder S. Cloning and characterization of the hamster and guinea pig nicotinic acid receptors. J. Lipid Res. 48 (2007) 2065-2071
49. Torrey E.F., Webster M., Knable M., Johnston N., and Yolken R.H. The Stanley Foundation brain collection and neuropathology consortium. Schizophr. Res. 44 (2000) 151-155
50. Turenne S.D., Seeman M., and Ross B.M. An animal model of nicotinic-acid induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. Schizophr. Res. 50 (2001) 191-197
51. Waldo M.C. Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophr. Res. 40 (1999) 49-53
52. Wang M., and Fotsch C. Small-molecule compounds that modulate lipolysis in adipose tissue: targeting strategies and molecular classes. Chem. Biol. 13 (2006) 1019-1027
53. Ward P.E., Sutherland J., Glen E.M.T., and Glen A.I.M. Niacin skin flush in schizophrenia: a preliminary report. Schizophr. Res. 29 (1998) 269-274
54. Weis S., Llenos I.C., Dulay J.R., Elashoff M., Martínez-Murillo F., and Miller C.L. Quality control for microarray analysis of human brain samples: the impact of postmortem factors, RNA characteristics, and histopathology. J. Neurosci. Methods 165 (2007) 198-209
55. Wise A., Foord S.M., Fraser N.J., Barnes A.A., Elshourbagy N., Eilert M., Ignar D.M., Murdock P.R., Steplewski K., Green A., Brown A.J., Dowel S.J., Szekeres P.G., Hassall D.F., Marshall F.H., Wilson S., and Pike N.B. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278 (2003) 9869-9874
56. Zhang Y., Schmidt R.J., Foxworthy P., Emkey R., Oler J.K., Large T.H., Wang H., Su E.W., Mosior M.K., Eacho P.I., and Cao G. Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem. Biophys. Res. Commun. 334 (2005) 729-732